South Korea · Delayed Price · Currency is KRW Seoul Pharma Statistics
Total Valuation
Seoul Pharma has a market cap or net worth of KRW 22.81 billion. The enterprise value is 21.04 billion.
| Market Cap | 22.81B |
| Enterprise Value | 21.04B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Seoul Pharma has 11.66 million shares outstanding.
| Current Share Class | 11.66M |
| Shares Outstanding | 11.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | n/a |
| Float | 4.72M |
Valuation Ratios
The trailing PE ratio is 13.11.
| PE Ratio | 13.11 |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | 2.55 |
| P/OCF Ratio | 2.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.18, with an EV/FCF ratio of 2.36.
| EV / Earnings | 12.10 |
| EV / Sales | 0.41 |
| EV / EBITDA | 11.18 |
| EV / EBIT | n/a |
| EV / FCF | 2.36 |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.45 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 8.00 |
| Debt / FCF | 1.69 |
| Interest Coverage | -1.35 |
Financial Efficiency
Return on equity (ROE) is 4.39% and return on invested capital (ROIC) is -1.98%.
| Return on Equity (ROE) | 4.39% |
| Return on Assets (ROA) | -0.69% |
| Return on Invested Capital (ROIC) | -1.98% |
| Return on Capital Employed (ROCE) | -1.68% |
| Weighted Average Cost of Capital (WACC) | 5.42% |
| Revenue Per Employee | 296.96M |
| Profits Per Employee | 10.11M |
| Employee Count | 172 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.74 |
Taxes
| Income Tax | -68.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.07% in the last 52 weeks. The beta is 0.50, so Seoul Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -39.07% |
| 50-Day Moving Average | 2,044.54 |
| 200-Day Moving Average | 2,580.16 |
| Relative Strength Index (RSI) | 42.86 |
| Average Volume (20 Days) | 8,099 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Seoul Pharma had revenue of KRW 51.08 billion and earned 1.74 billion in profits.
| Revenue | 51.08B |
| Gross Profit | 30.32B |
| Operating Income | -779.94M |
| Pretax Income | 1.67B |
| Net Income | 1.74B |
| EBITDA | 1.88B |
| EBIT | -779.94M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 16.82 billion in cash and 15.05 billion in debt, with a net cash position of 1.77 billion or 151.49 per share.
| Cash & Cash Equivalents | 16.82B |
| Total Debt | 15.05B |
| Net Cash | 1.77B |
| Net Cash Per Share | 151.49 |
| Equity (Book Value) | 40.54B |
| Book Value Per Share | n/a |
| Working Capital | 9.75B |
Cash Flow
In the last 12 months, operating cash flow was 9.77 billion and capital expenditures -843.01 million, giving a free cash flow of 8.93 billion.
| Operating Cash Flow | 9.77B |
| Capital Expenditures | -843.01M |
| Depreciation & Amortization | 2.66B |
| Net Borrowing | -2.68B |
| Free Cash Flow | 8.93B |
| FCF Per Share | 765.73 |
Margins
Gross margin is 59.36%, with operating and profit margins of -1.53% and 3.40%.
| Gross Margin | 59.36% |
| Operating Margin | -1.53% |
| Pretax Margin | 3.27% |
| Profit Margin | 3.40% |
| EBITDA Margin | 3.68% |
| EBIT Margin | -1.53% |
| FCF Margin | 17.48% |
Dividends & Yields
This stock pays an annual dividend of 40.00, which amounts to a dividend yield of 2.04%.
| Dividend Per Share | 40.00 |
| Dividend Yield | 2.04% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 2.04% |
| Earnings Yield | 7.62% |
| FCF Yield | 39.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.
| Last Split Date | Apr 12, 2004 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Seoul Pharma has an Altman Z-Score of 1.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.73 |
| Piotroski F-Score | 3 |